Marco Ardigo
Overview
Explore the profile of Marco Ardigo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Starace M, Mandel V, Ardigo M, Carpanese M, Quadrelli F, Pampaloni F, et al.
Dermatol Ther (Heidelb)
. 2025 Mar;
PMID: 40064753
Introduction: Literature about trichoscopy of permanent chemotherapy-induced alopecia (pCIA) is still scarce, while no data were published regarding reflectance confocal microscopy (RCM). The aim of our study is to monitor...
2.
Ardigo M, Flenghi L, Ibatici A, Massone C, Quaglino P, Teoli M, et al.
Ital J Dermatol Venerol
. 2025 Mar;
PMID: 40042219
Mogamulizumab is a humanized monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity that targets chemokine receptor type. Several clinical trials and real-life experiences confirmed the efficacy and safety profiles of mogamulizumab...
3.
Valenti M, Di Giulio S, Carugno A, Frascione P, Marzano A, Mercuri S, et al.
Dermatol Reports
. 2025 Feb;
PMID: 39964052
Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across...
4.
Starace M, De Carvalho N, Melo D, Cedirian S, Mandel V, Machado C, et al.
Dermatol Pract Concept
. 2024 Dec;
14(4).
PMID: 39652914
Objectives: Alopecia areata incognita is a non-scarring autoimmune hair loss condition primarily affecting women aged 20 to 40. It is often misdiagnosed due to its resemblance to other conditions. Diagnosis...
5.
Geskin L, Querfeld C, Hodak E, Nikbakht N, Papadavid E, Ardigo M, et al.
Dermatol Ther (Heidelb)
. 2024 Nov;
15(1):61-73.
PMID: 39602063
Background: Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma. While multiple guidelines provide treatment recommendations, there are currently no clear treatment algorithms for MF. Chlormethine...
6.
Valenti M, DArino A, Melis E, Carugno A, Sena P, Frascione P, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518584
Melanoma is currently the most prevalent malignant neoplasm among adults and represents the second most common cancer in both sexes among individuals aged 0 to 39 years. This retrospective multicenter...
7.
Violetti S, Ardigo M, Fava P, Gritti G, Morsia E, Onida F, et al.
Drugs Context
. 2024 Oct;
13.
PMID: 39416772
Topical chlormethine (CL) gel formulation was approved by the EMA in 2017 for the treatment of adult patients with mycosis fungoides (MF). To expand the knowledge on the management of...
8.
Argenziano G, Ardigo M, Micali G, Nasca M, Scilletta A, Tognetti L, et al.
Dermatol Pract Concept
. 2024 Oct;
14(4).
PMID: 39392426
Introduction: Antibiotic resistance has become a serious, severe problem worldwide. This issue does not only relate to the use of systemic antibiotics but to topical ones as well, like systemic...
9.
Ardigo M
Dermatol Reports
. 2024 Sep;
16(Suppl 2):9814.
PMID: 39295885
In clinical practice, cutaneous lymphomas can be challenging to diagnose or even suspect because they mimic a variety of other inflammatory and neoplastic dermatological conditions. Support for non-invasive skin analysis...
10.
Paolino G, Pampena R, Di Ciaccio S, Carugno A, Cantisani C, Di Nicola M, et al.
Medicina (Kaunas)
. 2024 Aug;
60(8).
PMID: 39202520
: Amelanotic/hypomelanotic melanomas (AHMs) account for 2-8% of all cutaneous melanomas. Due to their clinical appearance and the lack of specific dermoscopic indicators, AHMs are challenging to diagnose, particularly in...